未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306 一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的食管鳞状细胞癌: 原理306的回顾性分析 Xu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H. 分享 收藏
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305 一线Tislelizumab联合化疗治疗程序性死亡配体1表达 ≥ 1% 的晚期胃癌: 原理305的回顾性分析 Moehler, Markus; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Lee, Keun-Wook; Rha, Sun Young; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Wyrwicz, Lucjan; Disel, Umut; Pazo-Cid, Roberto A.; Fornaro, Lorenzo; Xu, Yaling; Sheng, Tao; Yang, Silu; Kadva, Alysha; Cruz-Correa, Marcia; Xu, Rui-Hua 分享 收藏
Conversion Therapy for Stage IV Gastric Cancer: Report From the Expert Consensus Meeting at KINGCA WEEK 2024 Kim, Tae-Han; Uyama, Ichiro; Rha, Sun Young; Bencivenga, Maria; An, Jiyeong; Wyrwicz, Lucjan; Koo, Dong-Hoe; van Hillegersberg, Richard; Lee, Keun-Wook; Li, Guoxin; Yoshikawa, Takaki; Badgwell, Brian; Lorenzen, Sylvie; Kim, In-Ho; Lee, In-Seob; Han, Hye-Sook; Hoon, Hur 分享 收藏
Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+advanced, unresectable or metastatic G/GEJ adenocarcinoma KEYNOTE-811研究的III期最终总生存数据，该研究评估了帕博利珠单抗联合曲妥珠单抗和化疗治疗HER2阳性、不可切除或转移性胃/胃食管结合部腺癌。 Rha, S. Y.; Kawazoe, A.; Bai, Y.; Xu, J.; Lonardi, S.; Metges, J-P.; Weber, P. E. Yanez; Wyrwicz, L. S.; Shen, L.; Ostapenko, Y. V.; Bilici, M.; Chung, H. C.; Shitara, K.; Mahave, M.; van Cutsem, E.; Tabernero, J.; Xu, L.; Sharan, K. P.; Bhagia, P.; Janjigian, Y. Y. 分享 收藏
Neoadjuvant and adjuvant pembrolizumab (pembro) plus chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study 新辅助和辅助帕博利珠单抗（pembro）联合化疗（chemo）治疗局部晚期胃或胃食管结合部（G/GEJ）癌：KEYNOTE-585 III期研究的患者报告结局（PROs） Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y-K.; Al-Batran, S-E.; Yoshikawa, T.; Weber, P. E. Yanez; Di Bartolomeo, M.; Lonardi, S.; Guan, Y.; Valderrama, A.; Shih, C-S.; Fang, X.; Bang, Y-J. 分享 收藏
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up 替雷利珠单抗（TIS）联合化疗（CT）对比安慰剂（PBO）联合化疗（CT）治疗HER2阴性晚期或转移性胃或胃食管结合部腺癌（GC/GEJC）：RATIONALE-305研究至少3年生存随访 Cruz-Correa, M.; Oh, D-Y.; Kato, K.; Tabernero, J.; Bai, Y.; Shi, J.; Lee, K-W.; Hirano, H.; Spigel, D. R.; Wyrwicz, L. S.; Pazo Cid, R. A.; Cubillo Gracian, A.; Li, L.; Xu, Y.; Sheng, T.; Yang, S.; Xu, R-H.; Moehler, M. 分享 收藏
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer 阳光的通俗易懂的总结: 三氟尿苷/替匹拉西和贝伐单抗治疗难治性转移性结直肠癌 Prager, Gerald W.; Taieb, Julien; Fakih, Marwan; Ciardiello, Fortunato; Cutsem, Eric Van; Elez, Elena; Wyrwicz, Lucjan; Stroyakovskiy, Daniil; Liposits, Gabor; Bondarenko, Igor; Modest, Dominik P.; Amellal, Nadia; Tabernero, Josep 分享 收藏
Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306 Raymond, E.; Xu, J.; Kato, K.; Hubner, R.; Shu, Y.; Park, S. R.; Kojima, T.; Wyrwicz, L. S.; Tougeron, D.; Geboes, K.; Van Cutsem, E.; Pazo Cid, R. A.; Zaanan, A.; McLachlan, S-A.; Wu, H.; Shi, J.; Li, L.; Yan, S.; Yoon, H. 分享 收藏
Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer Shitara, K.; Rha, S. Y.; Wyrwicz, L. S.; Oshima, T.; Karaseva, N.; Osipov, M.; Yasui, H.; Yabusaki, H.; Afanasyev, S.; Park, Y-K.; Al-Batran, S-E.; Yoshikawa, T.; Weber, P. E. Yanez; Di Bartolomeo, M.; Lonardi, S.; Fang, X.; Shih, C-S.; Bhagia, P.; Bang, Y-J. 分享 收藏
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial Tislelizumab加化疗与安慰剂加化疗作为晚期胃或胃食管交界处腺癌的一线治疗: 原理305的随机，双盲，3期试验 Qiu, Miao-Zhen; Oh, Do-Youn; Kato, Ken; Arkenau, Tobias; Tabernero, Josep; Correa, Marcia Cruz; Zimina, Anastasia, V; Bai, Yuxian; Shi, Jianhua; Lee, Keun-Wook; Wang, Jufeng; Poddubskaya, Elena; Pan, Hongming; Rha, Sun Young; Zhang, Ruixing; Hirano, Hidekazu; Spigel, David; Yamaguchi, Kensei; Chao, Yee; Wyrwicz, Lucjan; Disel, Umut; Cid, Roberto Pazo; Fornaro, Lorenzo; Evesque, Ludovic; Wang, Hongwei; Xu, Yaling; Li, Jiang; Sheng, Tao; Yang, Silu; Li, Liyun; Moehler, Markus; Xu, Rui-Hua 分享 收藏
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN Blay, Jean-Yves; Casali, Paolo; Ray-Coquard, Isabelle; Seckl, Michael J.; Gietema, Jourik; de Herder, Wouter W.; Caplin, Martyn; Klumpen, Heinz-Josef; Glehen, Olivier; Wyrwicz, Lucjan; Peeters, Robin; Licitra, Lisa; Girard, Nicolas; Piperno-Neumann, Sophie; Kapiteijn, Ellen; Idbaih, Ahmed; Franceschi, Enrico; Trama, Annalisa; Frezza, Anna-Maria; Hohenberger, Peter; Hindi, Nadia; Martin-Broto, Javier; Schell, Johanna; Rogasik, Muriel; Lejeune, Stephane; Oliver, Kathy; de Lorenzo, Francesco; Weinmanv, Ariane 分享 收藏
分享 收藏
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial Rivoceranib，一种VEGFR-2抑制剂，单药治疗先前治疗的晚期或转移性胃或胃食管交界处癌患者 (ANGEL研究): 一项国际，随机，安慰剂对照，3期试验 Kang, Yoon-Koo; Ryu, Min-Hee; Di Bartolomeo, Maria; Chau, Ian; Yoon, Harry; Kim, Jong Gwang; Lee, Keun-Wook; Oh, Sang Chul; Takashima, Atsuo; Kryzhanivska, Anna; Chao, Yee; Evesque, Ludovic; Schenker, Michael; Mcginn, Arlo; Zhao, Yufan; Lee, Jennifer; Wyrwicz, Lucjan; Boku, Narikazu 分享 收藏
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial Pembrolizumab联合曲妥珠单抗和化疗治疗HER2-positive胃或胃食管交界处腺癌: 来自3期KEYNOTE-811随机安慰剂对照试验的中期分析 Janjigian, Yelena Y.; Kawazoe, Akihito; Bai, Yuxian; Xu, Jianming; Lonardi, Sara; Metges, Jean Phillipe; Yanez, Patricio; Wyrwicz, Lucjan S.; Shen, Lin; Ostapenko, Yuriy; Bilici, Mehmet; Chung, Hyun Cheol; Shitara, Kohei; Qin, Shu-Kui; Van Cutsem, Eric; Tabernero, Josep; Li, Kan; Shih, Chie-Schin; Bhagia, Pooja; Rha, Sun Young 分享 收藏
分享 收藏
Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study durvalumab联合5-氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛 (FLOT) 治疗可切除胃癌和胃食管交界癌 (GC/GEJC) 的病理完全缓解 (pCR): 全球III期马特洪峰研究的中期结果 Oh, D-Y.; Janjigian, Y. Y.; Al-Batran, S-E.; Wainberg, Z. A.; van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L. S.; Omori, T.; Moehler, M.; Garrido, M.; Cunha Sousa Oliveira, S.; Liberman, M.; Castro Oliden, V.; Bilici, M.; Kurland, J.; Xynos, I.; Mann, H.; Tabernero, J. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
Nature Communications.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏